{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:57:20Z","timestamp":1777114640973,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,26]]},"DOI":"10.7759\/cureus.104285","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:37:23Z","timestamp":1772109443000},"source":"Crossref","is-referenced-by-count":1,"title":["Obinutuzumab Treatment in Rituximab- and Bortezomib-Resistant Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy"],"prefix":"10.7759","author":[{"given":"Uygar","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sultan","family":"Ozkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Ugur","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040607","article-title":"Advances in membranous nephropathy","volume":"10","author":"Ronco P","year":"2021","unstructured":"Ronco P, Plaisier E, Debiec H. Advances in membranous nephropathy. J Clin Med. 2021, 10:607. 10.3390\/jcm10040607","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck LH Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, et al.. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009, 361:11-21. 10.1056\/NEJMoa0810457","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases","volume":"100","year":"2021","unstructured":"KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases. Kidney Int. 2021, 100.S1-S276. 10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti P","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Chianca A, et al.. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012, 23:1416-25. 10.1681\/ASN.2012020181","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza FC","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al.. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019, 381:36-46. 10.1056\/NEJMoa1814427","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand JA","year":"2017","unstructured":"van den Brand JA, Ruggenenti P, Chianca A, et al.. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol. 2017, 28:2729-37. 10.1681\/ASN.2016091022","journal-title":"J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab","volume":"93","author":"van de Logt AE","year":"2018","unstructured":"van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, Wetzels J. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018, 93:1016-7. 10.1016\/j.kint.2017.12.019","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000515087","article-title":"Bortezomib treatment for refractory PLA2R-positive membranous nephropathy","volume":"1","author":"Geara AS","year":"2021","unstructured":"Geara AS, Bhoj V, Hogan JJ. Bortezomib treatment for refractory PLA2R-positive membranous nephropathy. Glomerular Dis. 2021, 1:40-3. 10.1159\/000515087","journal-title":"Glomerular Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2016.0350","article-title":"Bortezomib as a novel approach to early recurrent membranous glomerulonephritis after kidney transplant refractory to combined conventional rituximab therapy","volume":"15","author":"Barbari A","year":"2017","unstructured":"Barbari A, Chehadi R, Kfoury Assouf H, et al.. Bortezomib as a novel approach to early recurrent membranous glomerulonephritis after kidney transplant refractory to combined conventional rituximab therapy. Exp Clin Transplant. 2017, 15:350-4. 10.6002\/ect.2016.0350","journal-title":"Exp Clin Transplant"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy V","year":"2017","unstructured":"Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, Leandro MJ. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017, 56:1227-37. 10.1093\/rheumatology\/kex067","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie RA","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, et al.. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022, 81:100-7. 10.1136\/annrheumdis-2021-220920","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner E","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, et al.. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010, 115:4393-402. 10.1182\/blood-2009-06-225979","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi S","year":"2020","unstructured":"Sethi S, Kumar S, Lim K, Jordan SC. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep. 2020, 5:1515-8. 10.1016\/j.ekir.2020.06.030","journal-title":"Kidney Int Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA(2)R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit N","year":"2020","unstructured":"Klomjit N, Fervenza FC, Zand L. Successful treatment of patients with refractory PLA(2)R-associated membranous nephropathy with obinutuzumab: a report of 3 cases. Am J Kidney Dis. 2020, 76:883-8. 10.1053\/j.ajkd.2020.02.444","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02761-3","article-title":"Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases","volume":"23","author":"Hudson R","year":"2022","unstructured":"Hudson R, Rawlings C, Mon SY, Jefferis J, John GT. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases. BMC Nephrol. 2022, 23:134. 10.1186\/s12882-022-02761-3","journal-title":"BMC Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100853","article-title":"Obinutuzumab in refractory membranous nephropathy: a case series","volume":"6","author":"Lin Y","year":"2024","unstructured":"Lin Y, Han Q, Chen L, et al.. Obinutuzumab in refractory membranous nephropathy: a case series. Kidney Med. 2024, 6:100853. 10.1016\/j.xkme.2024.100853","journal-title":"Kidney Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese AS","year":"2017","unstructured":"De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017, 28:421-30. 10.1681\/ASN.2016070776","journal-title":"J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.04.011","article-title":"Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy","volume":"100","author":"Salhi S","year":"2021","unstructured":"Salhi S, Ribes D, Colombat M, Fortenfant F, Faguer S. Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy. Kidney Int. 2021, 100:708-9. 10.1016\/j.kint.2021.04.011","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-013-0028-x","article-title":"Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy","volume":"27","author":"Hartono C","year":"2014","unstructured":"Hartono C, Chung M, Kuo SF, Seshan SV, Muthukumar T. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J Nephrol. 2014, 27:103-6. 10.1007\/s40620-013-0028-x","journal-title":"J Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production","volume":"9","author":"Perry DK","year":"2009","unstructured":"Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009, 9:201-9. 10.1111\/j.1600-6143.2008.02461.x","journal-title":"Am J Transplant"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield RR","year":"2019","unstructured":"Redfield RR, Jordan SC, Busque S, et al.. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant. 2019, 19:3035-45. 10.1111\/ajt.15514","journal-title":"Am J Transplant"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab250","article-title":"Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab","volume":"15","author":"Ginth\u00f6r NE","year":"2022","unstructured":"Ginth\u00f6r NE, Artinger K, Pollheimer MJ, Stradner MH, Eller K. Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab. Clin Kidney J. 2022, 15:564-6. 10.1093\/ckj\/sfab250","journal-title":"Clin Kidney J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-025-02224-6","article-title":"Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy: a case-series","volume":"38","author":"Sridharan K","year":"2025","unstructured":"Sridharan K, Gopal B, Wilson S, Pham A, Hutton H. Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy: a case-series. J Nephrol. 2025, 38:1809-18. 10.1007\/s40620-025-02224-6","journal-title":"J Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.25259\/ijn_498_23","article-title":"Obinutuzumab in difficult to treat phospholipase A2 receptor positive membranous nephropathy: our experience at a Tertiary Care Center in North India","volume":"35","author":"Jha VK","year":"2025","unstructured":"Jha VK, Panda SK, Rai SK, Srivastava AK. Obinutuzumab in difficult to treat phospholipase A2 receptor positive membranous nephropathy: our experience at a Tertiary Care Center in North India. Indian J Nephrol. 2025, 35:91-6. 10.25259\/ijn_498_23","journal-title":"Indian J Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae299","article-title":"Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic","volume":"17","author":"Xu M","year":"2024","unstructured":"Xu M, Chen R, Wang Y, et al.. Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic. Clin Kidney J. 2024, 17:sfae299. 10.1093\/ckj\/sfae299","journal-title":"Clin Kidney J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452190-obinutuzumab-treatment-in-rituximab--and-bortezomib-resistant-phospholipase-a2-receptor-antibody-positive-membranous-nephropathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:37:24Z","timestamp":1772109444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452190-obinutuzumab-treatment-in-rituximab--and-bortezomib-resistant-phospholipase-a2-receptor-antibody-positive-membranous-nephropathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.104285","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}